Role of systemic inflammatory response in predicting survival in patients with primary operable cancer

Future Oncology

Volumn 6, Issue 1, 2010, Pages 149-163

  Roxburgh, Campbell S D ^a   McMillan, Donald C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cancer; Surgery; Survival; Systemic inflammation

Indexed keywords

ALBUMIN; ALPHA 1 ANTICHYMOTRYPSIN; C REACTIVE PROTEIN; INTERLEUKIN 6; OROSOMUCOID;

BLADDER CANCER; BREAST CANCER; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; ESOPHAGUS CANCER; GASTROESOPHAGEAL CANCER; GLASGOW OUTCOME SCALE; HUMAN; HYPOALBUMINEMIA; KIDNEY CARCINOMA; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NEUTROPHIL COUNT; OPERABLE CANCER; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE COUNT; TREATMENT RESPONSE;

DISEASE PROGRESSION; HUMANS; INFLAMMATION; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 75149189004     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.136     Document Type: Review

References (130)

1. MacDonald N: Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care. J. Support. Oncol. 5, 157-162 (2007).
2. Coussens LM, Werb Z: Inflammation and cancer. Nature 420(6917), 860-867 (2002).
3. Vakkila J, Lotze MT: Inflammation and necrosis promote tumour growth. Nat. Rev. Immunol. 4, 641-648 (2004).
4. DeNardo DG, Johansson M, Coussens LM: Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 27(1), 11-18 (2008).
5. Gabay C, Kuschner I: Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340(17), 1376 (1999).
6. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267(5203), 1456-1462 (1995).
7. DeWys WD, Begg C, Lavin PT etal.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491-497 (1980).
8. Graf W, Bergstrom R, Pahlman L, GlimeliusB: Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur. J. Cancer 30(4), 453-457 (1994).
9. Maltoni M, Caraceni A, Brunelli C et al.; Steering Committee of the European Association for Palliative Care: Prognostic factors in advanced cancer patients: evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care. J. Clin. Oncol. 23(25), 6240-6248 (2005).
10. McMillan DC: An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc. Nutr. Soc. 67(3), 257-262 (2008). ■■ Describes the rationale and development of the first systemic inflammation-based prognostic score for patients with cancer.
11. McMillan DC, Preston T, Watson WS etal.: Relationship between weight loss, reduction of body cell mass and inflammatory response in patients with cancer. Br. J. Surg. 81(7), 1011-1014 (1994).
12. Falconer JS, Fearon KC, Ross JA et al.: Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75(8), 2077-2082 (1995).
13. McMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS: Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr. Cancer 31(2), 101-105 (1998).
14. O'Gorman P, McMillan DC, McArdle CS: Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. Nutr. Cancer 35(2), 127-129 (1999).
15. Barber MD, Ross JA, Fearon KC: Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr. Cancer 35(2), 106-110 (1999).
16. McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE, McArdle CS: A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br. J. Cancer 79(3-4), 495-500 (1999).
17. Morley JE, Thomas DR, Wilson MM: Cachexia: pathophysiology and clinical relevance. Am. J. Clin. Nutr. 83(4), 735-743 (2006).
18. Fearon KC, Voss AC, Hustead DS; Cancer Cachexia Study Group: Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am. J. Clin. Nutr. 83(6), 1345-1350 (2006).
19. Nozoe T, Matsumata T, Sugimachi K: Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am. J. Clin. Oncol. 23, 263-266 (2000).
20. Du Klos TW, Mold C: C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol. Res. 30, 261-277 (2004).
21. Canna K, McArdle PA, McMillan DC et al.: The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br. J. Cancer 92, 651-654 (2005).
22. Roxburgh CSD, Salmond JM, Horgan PG, Oien KA, McMillan DC: Comparison of the prognostic value of inflammation based pathological and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann. Surg. 249(5), 788-793 (2009). ■■ A large study demonstrating that the systemic inflammatory response (Glasgow Prognostic Score [GPS]) predicts survival independent of tumor inflammatory infiltrate in operable colorectal cancer.
23. Condeelis J, Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124(2), 263-266 (2006).
24. Abramovitch R, Marikovsky M, Meir G, Neeman M: Stimulation of tumour growth by wound-derived growth factors. Br. J. Cancer 79, 1392-1398 (1999).
25. McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care 12, 223-226 (2009).
26. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ: Neutrophil- lymphocyte ratio as a prognostic factor in colorectal cancer. J. Surg. Oncol. 91, 181-184 (2005).
27. Smith RA, Bosonnet L, Raraty M et al.: Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am. J. Surg. 197(4), 466-472 (2009).
28. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br. J. Cancer 89, 1028-1030 (2003).
29. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br. J. Cancer 90(9), 1704-1706 (2004).
30. Wilop S, Crysandt M, Bendel M, MahnkenAH, Osieka R, Jost E: Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie 31(12), 665-670 (2008).
31. Koch A, Fohlin H, Sörenson S: Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J. Thorac. Oncol. 4(3), 326-332 (2009).
32. Nakahara K, Monden Y, Ohno K et al.: Importance of biologic status to the postoperative prognosis of patients with stageIII non-small cell lung cancer. J. Surg. Oncol. 36(3), 155-160 (1987).
33. Hara M, Matsuzaki Y, Shimuzu T et al.: Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res. 27(4), 3001-3004 (2007).
34. Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T: Prognostic impact of thrombocytosis in resectable non-small cell lung cancer. Interact. Cardiovasc. Thorac. Surg. 7(4), 613-615 (2008).
35. Kasprzyk M, Dyszkiewicz W, Zwaruń D, Leśniewska K, Wiktorowicz K: The assessment of acute phase proteins as prognostic factors in patients surgically treated for non-small cell lung cancer. Pneumonol. Alergol. Pol. 76(5), 321-326 (2008).
36. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E: Neutrophil/ lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 137(2), 425-428 (2009).
37. Lee JG, Cho BC, Bae MK et al.: Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer 63(1), 106-110 (2009).
38. Amar D, Zhang H, Park B, Heerdt PM, Fleisher M, Thaler HT: Inflammation and outcome after general thoracic surgery. Eur. J. Cardiothorac. Surg. 32(3), 431-434 (2007).
39. Göransson J, Jonsson S, Lasson A: Pre-operative plasma levels of C-reactive protein, albumin and various plasma protease inhibitors for the pre-operative assessment of operability and recurrence in cancer surgery. Eur. J. Surg. Oncol. 22(6), 607-617 (1996).
40. Longo WE, Virgo KS, Johnson FE et al.: Outcome after proctectomy for rectal cancer in Department of Veterans Affairs Hospitals: a report from the National Surgical Quality Improvement Program. Ann. Surg. 228(1), 64-70 (1998).
41. Heys SD, Walker LG, Deehan DJ, EreminOE: Serum albumin: a prognostic indicator in patients with colorectal cancer. J. R. Coll. Surg. Edinb. 43(3), 163-168 (1998).
42. Nozoe T, Matsumata T, Kitamura M, Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am. J. Surg. 176(4), 335-338 (1998).
43. Longo WE, Virgo KS, Johnson FE et al.: Risk factors for morbidity and mortality after colectomy for colon cancer. Dis. Colon Rectum 43(1), 83-91 (2000).
44. Nielsen HJ, Christensen IJ, Sørensen S, Moesgaard F, Brünner N: Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann. Surg. Oncol. 7(8), 617-623 (2000).
45. Wigmore SJ, McMahon AJ, Sturgeon CM, Fearon KC: Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. Br. J. Surg. 88(2), 255-260 (2001).
46. McMillan DC, Canna K, McArdle CS: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br. J. Surg. 90(2), 215-219 (2003).
47. Chung YC, Chang YF: Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur. J. Gastroenterol. Hepatol. 15(4), 369-373 (2003).
48. Miki C, Konishi N, Ojima E, Hatada T, Inoue Y, Kusunoki M: C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig. Dis. Sci. 49, 970-976 (2004).
49. Kandemir EG, Mayadagli A, Karagoz B, Bilgi O, Turken O, Yaylaci M: Prognostic significance of thrombocytosis in node-negative colon cancer. J. Int. Med. Res. 33(2), 228-235 (2005).
50. Nikiteas NI, Tzanakis N, Gazouli M et al.: Serum IL-6, TNFa and CRP levels in Greek colorectal cancer patients: prognostic implications. World J. Gastroenterol. 11, 1639-1643 (2005).
51. Cengiz O, Kocer B, Sürmeli S, Santicky MJ, Soran A: Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma? Med. Sci. Monit. 12(6), 240-247 (2006).
52. Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K: Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann. Surg. 246(6), 1047-1051 (2007). ■■ A large study with mature follow-up validating the prognostic value of the GPS in patients with operable colorectal cancer.
53. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS: Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int. J. Colorectal Dis. (8), 881-886 (2007).
54. Leitch EF, Chakrabarti M, Crozier JEM et al.: Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br. J. Cancer 97, 1266-1270 (2007).
55. Jamieson NB, Glen P, McMillan DC et al.: Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br. J. Cancer 92, 21-23 (2005).
56. Koike Y, Miki C, Okugawa Y et al.: Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J. Surg. Oncol. 98, 540-544 (2008).
57. Roxburgh CSD, Crozier JE, Maxwell F et al.: Comparison of tumour-based (Petersen Index) and inflammation-based (Glasgow Prognostic Score) scoring systems in patients undergoing curative resection for colon cancer. Br. J. Cancer 100(5), 701-706 (2009). ■ Compares the prognostic value of high-risk pathological factors and the GPS in colon cancer.
58. Roxburgh CSD, Wallace AM, Guthrie GK, Horgan PG, McMillan DC: The relationship between patient and tumour related factors, the systemic inflammatory response and cancer specific survival in patients under going potentially curative surgery for colorectal cancer. Colorectal Dis. (2009) (Epub ahead of print).
59. de Mello J, Struthers L, Turner R, Cooper EH, Giles GR: Multivariate analyses as aids to diagnosis and assessment of prognosis in gastrointestinal cancer. Br. J. Cancer 48(3), 341-348 (1983).
60. Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zamcheck N, Cohen AS: Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand. J. Immunol. 19(3), 193-198 (1984).
61. McMillan DC, Wotherspoon HA, Fearon KC, Sturgeon C, Cooke TG, McArdle CS: A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am. J. Surg. 170(4), 319-322 (1995).
62. Tartter PI: Pretreatment prognostic factors in colorectal cancer patients with synchronous liver metastases. Eur. J. Surg. Oncol. 13(6), 485-491 (1987).
63. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN: Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann. Surg. Oncol. 16(3), 614-622 (2009).
64. Wong VK, Malik HZ, Hamady ZZ et al.: C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br. J. Cancer 96(2), 222-225 (2007).
65. Sasaki A, Kai S, Endo Y et al.: Prognostic value of preoperative peripheral blood monocyte count in patients with colorectal liver metastasis after liver resection. J. Gastrointest. Surg. 11(5), 596-602 (2007).
66. Malik HZ, Prasad KR, Halazun KJ et al.: Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann. Surg. 246(5), 806-814 (2007). ■■ A large study with mature follow-up reporting the prognostic value of various markers of the systemic inflammatory response in patients with colorectal liver metastases.
67. Halazun KJ, Aldoori A, Malik HZ et al.: Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur. J. Surg. Oncol. 34(1), 55-60 (2008).
68. Gomez D, Morris-Stiff G, Wyatt J, Toogood GJ, Lodge JP, Prasad KR: Surgical technique and systemic inflammation influences long-term disease-free survival following hepatic resection for colorectal metastasis. J. Surg. Oncol. 98(5), 371-376 (2008).
69. Ishizuka M, Kita J, Shimoda M et al.: Systemic inflammatory response predicts postoperative outcome in patients with liver metastases from colorectal cancer. J. Surg. Oncol. 100(1), 38-42 (2009).
70. Neal CP, Mann CD, Sutton CD et al.: Evaluation of the prognostic value of systemic inflammation and socio-economic deprivation in patients with resectable colorectal liver metastases. Eur. J. Cancer 45(1), 56-64 (2009).
71. Hashimoto K, Ikeda Y, Korenaga D et al.: The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103(9), 1856-1864 (2005).
72. Gerhardt T, Milz S, Schepke M et al.: C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J. Gastroenterol. 12(34), 5495-5500 (2006).
73. Nagaoka S, Yoshida T, Akiyoshi J et al.: Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 27(8), 1091-1097 (2007).
74. Gomez D, Farid S, Malik HZ et al.: Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J. Surg. 32(8), 1757-1762 (2008).
75. Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR: Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J. Surg. Oncol. 97(6), 513-518 (2008).
76. Nozoe T, Saeki H, Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am. J. Surg. 182(2), 197-201 (2001).
77. Ikeda M, Furukawa H, Imamura H et al.: Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann. Surg. Oncol. 9(3), 287-291 (2002).
78. Shimada H, Nabeya Y, Okazumi S et al.: Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J. Surg. Oncol. 83(4), 248-252 (2003).
79. Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T: Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann. Surg. 238(2), 197-202 (2003).
80. Shimada H, Oohira G, Okazumi S et al.: Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J. Am. Coll. Surg. 198(5), 737-741 (2004).
81. Guillem P, Triboulet JP: Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis. Esophagus 18(3), 146-150 (2005).
82. Gockel I, Dirksen K, Messow CM, Junginger T: Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J. Gastroenterol. 12(23), 3746-3750 (2006). ■ A large study reporting the prognostic value of preoperative C-reactive protein in operable esophageal cancer patients.
83. Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC: An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br. J. Cancer 94(11), 1568-1571 (2006). ■ Reports the prognostic value of pre-operative C-reactive protein in operable gastro-esophageal cancer patients.
84. Kobayashi T, Teruya M, Kishiki T et al.: Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. Surgery 144(5), 729-735 (2008). ■■ Reports that the GPS is an important predictor of postoperative outcome when measured prior to neoadjuvant radiotherapy in esophageal cancer patients.
85. Wang CY, Hsieh MJ, Chiu YC et al.: Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother. Oncol. 92(2), 270-275 (2009).
86. Ueno H, Okada S, Okusaka T, Ikeda M: Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 59(4), 296-301 (2000).
87. Engelken FJ, Bettschart V, Rahman MQ, Parks RW, Garden OJ: Prognostic factors in the palliation of pancreatic cancer. Eur. J. Surg. Oncol. 29(4), 368-373 (2003).
88. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ: Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 6(5), 450-453 (2006).
89. Pine JK, Fusai KG, Young R et al.: Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur. J. Surg. Oncol. 35(6), 605-610 (2009).
90. Schwarz RE, Keny H: Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. Hepatogastroenterology 48(41), 1493-1498 (2001).
91. Suzuki K, Aiura K, Kitagou M et al.: Platelets counts closely correlate with the disease-free survival interval of pancreatic cancer patients. Hepatogastroenterology 51(57), 847-853 (2004).
92. Jamieson NB, Glen P, McMillan DC et al.: Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br. J. Cancer 92(1), 21-23 (2005).
93. Taucher S, Salat A, Gnant M et al.; Austrian Breast and Colorectal Cancer Study Group: Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb. Haemost. 89(6), 1098-1106 (2003).
94. Lis CG, Grutsch JF, Vashi PG, Lammersfeld CA: Is serum albumin an independent predictor of survival in patients with breast cancer? JPEN J. Parenter. Enteral Nutr. 27(1), 10-15 (2003).
95. Al Murri AM, Wilson C, Lannigan A et al.: Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br. J. Cancer 96(6), 891-895 (2007).
96. Pierce BL, Ballard-Barbash R, Bernstein L et al.: Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol. 27(21), 3437-3444 (2009).
97. Menczer J, Schejter E, Geva D, Ginath S, Zakut H: Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur. J. Gynaecol. Oncol. 19(1), 82-84 (1998).
98. Kodama J, Miyagi Y, Seki N et al.: Serum C-reactive protein as a prognostic factor in patients with epithelialovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 82(1), 107-110 (1999).
99. Cho H, Hur HW, Kim SW et al.: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol. Immunother. 58(1), 15-23 (2009).
100. Bozkurt N, Yuce K, Basaran M, Kose F, Ayhan A: Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer. Obstet. Gynecol. 103(1), 82-85 (2004).
101. Li AJ, Madden AC, Cass I, Leuchter RS, Lagasse LD, Karlan BY: The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol. Oncol. 92(1), 211-214 (2004).
102. Zhao C, Annamalai L, Guo C et al.: Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia 9(1), 1-7 (2007).
103. Hefler LA, Concin N, Hofstetter G et al.: Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin. Cancer Res. 14(3), 710-714 (2008). ■ This large study with mature follow-up reports the prognostic value of pre-operative C-reactive protein in operable ovarian cancer patients.
104. Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L: The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch. Gynecol. Obstet. 279(1), 53-56 (2009).
105. Zeimet AG, Marth C, Müller-Holzner E, Daxenbichler G, Dapunt O: Significance of thrombocytosis in patients with epithelial ovarian cancer. Am. J. Obstet. Gynecol. 170(2), 549-554 (1994).
106. de Jong D, Eijkemans MJ, Lie Fong S et al.: Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma. Oncology 72(5-6), 293-301 (2007).
107. Sharma R, Hook J, Kumar M, Gabra H: Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur. J. Cancer 44(2), 251-256 (2008).
108. McArdle PA, Mir K, Almushatat AS, WallaceAM, Underwood MA, McMillanDC: Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol. Int. 77(2), 127-129 (2006).
109. Beer TM, Lalani AS, Lee S et al.; ASCENT Investigators: C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 112(11), 2377-2383 (2008).
110. Nakashima J, Kikuchi E, Miyajima A et al.: Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases. Urol. Int. 80(2), 129-133 (2008).
111. Hilmy M, Bartlett JM, Underwood MA, McMillan DC: The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br. J. Cancer 92(4), 625-627 (2005).
112. Yoshida S, Saito K, Koga F et al.: C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 101(8), 978-981 (2008).
113. Masuda H, Kurita Y, Fukuta K, Mugiya S, Suzuki K, Fujita K: Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int. J. Urol. 5(5), 418-422 (1998).
114. O'Keefe SC, Marshall FF, Issa MM, HarmonMP, Petros JA: Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J. Urol. 168(4), 1378-1380 (2002).
115. Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B: Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. Eur. J. Cancer Prev. 11(3), 245-252 (2002).
116. Inoue K, Kohashikawa K, Suzuki S, ShimadaM, Yoshida H: Prognostic significance of thrombocytosis in renal cell carcinoma patients. Int. J. Urol. 11(6), 364-367 (2004).
117. Gogus C, Baltaci S, Filiz E, Elhan A, Bedük Y: Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 63(3), 447-450 (2004).
118. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M: Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int. J. Urol. 13(11), 1365-1370 (2006).
119. Bensalah K, Leray E, Fergelot P et al.: Prognostic value of thrombocytosis in renal cell carcinoma. J. Urol. 175(3), 859-863 (2006). ■ Large study that reports the prognostic value of pre-operative thrombocytosis in patients with renal cell carcinoma.
120. Lee SE, Byun SS, Han JH, Han BK, HongSK: Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma. BJU Int. 98(6), 1228-1232 (2006).
121. Lamb GW, McMillan DC, Ramsey S, Aitchison M: The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br. J. Cancer 94(6), 781-784 (2006).
122. Karakiewicz PI, Hutterer GC, Trinh QD et al.: C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313patients. Cancer 110(6), 1241-1247 (2007).
123. Komai Y, Saito K, Sakai K, Morimoto S: Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 99(1), 77-80 (2007).
124. Saito K, Kawakami S, Ohtsuka Y et al.: The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 100(2), 269-273 (2007).
125. Erdemir F, Kilciler M, Bedir S, Ozgok Y, Coban H, Erten K: Clinical significance of platelet count in patients with renal cell carcinoma. Urol. Int. 79(2), 111-116 (2007).
126. Ramsey S, Lamb GW, Aitchison M, McMillan DC: Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int. 101(8), 959-963 (2008). ■ Reports the comparison of the prognostic value of C-reactive protein and existing scoring systems in operable renal cancer.
127. Iimura Y, Saito K, Fujii Y et al.: Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J. Urol. 181(3), 1004-1012 (2009). ■■ Large study that reports the prognostic value of C-reactive protein in renal cancer and the development of a new prognostic score combining TNM stage and C-reactive protein (TNM-C score).
128. Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC: Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109(2), 205-212 (2007).
129. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7), 1073-1081 (2009).
130. Cancerstats (2004) www.cancerresearchuk.org.